Shares of Kadmon Holdings Inc. (KDMN) are rising over 11% in pre-market today, after the company announced positive topline results from the primary analysis of ROCKstar (KD025-213), the pivotal trial evaluating belumosudil (KD025) in patients with chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of systemic therapy.
from RTT - Before the Bell https://ift.tt/36knaJg
via IFTTT
No comments:
Post a Comment